AVTX
Avalo Therapeutics Inc
$
15.050
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
15.620
Open
15.330
VWAP
14.84
Vol
623.05K
Mkt Cap
272.92M
Low
14.160
Amount
9.25M
EV/EBITDA(TTM)
--
Total Shares
1.03M
EV
161.30M
EV/OCF(TTM)
--
P/S(TTM)
893.13
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
0.00
-100%
-1.449
-81.78%
--
--
-1.622
+29.73%
--
--
-1.567
-18.4%
Estimates Revision
The market is revising No Change the revenue expectations for Avalo Therapeutics, Inc. (AVTX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 67.13%.
EPS Estimates for FY2025
Revise Downward
-5.72%
In Past 3 Month
Stock Price
Go Up
+67.13%
In Past 3 Month
8 Analyst Rating
Wall Street analysts forecast AVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTX is 33.96 USD with a low forecast of 19.79 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.050
Low
19.79
Averages
33.96
High
48.00
Current: 15.050
Low
19.79
Averages
33.96
High
48.00
Oppenheimer
Oppenheimer
Outperform
maintain
$35
2025-09-15
Reason
Oppenheimer
Oppenheimer
Price Target
$35
2025-09-15
maintain
Outperform
Reason
Oppenheimer recommends investors to be buyers of Avalo Therapeutics in anticipation of the presentation of lutikizumab's open-label Phase 2 data in about 40 treatment-naive hidradenitis suppurativa patients late this week. The firm, which forecasts "strong results for luti" at the EADV conference given its substantial benefit previously shown in a difficult-to-treat, TNF-refractory disease population, would expect '009 - with its multiple advantages over luti - to show "at least as good as, and potentially better, efficacy" when LOTUS reads out in mid-2026, says the analyst. The firm has an Outperform rating and $35 price target on Avalo shares.
TD Cowen
Stacy Ku
Buy
initiated
2025-09-05
Reason
TD Cowen
Stacy Ku
Price Target
2025-09-05
initiated
Buy
Reason
TD Cowen analyst Stacy Ku initiated coverage of Avalo Therapeutics with a Buy rating and no price target. The company's AVTX-009 is in a Phase II trial for hidradenitis suppurativa, with data expected in mid-2026, the analyst tells investors in a research note. The firm says key opinion leaders highlight the heterogeneous patient population and high unmet need. The leaders expect success with AVTX-009 with potential for a $1B-plus sales opportunity.
Cantor Fitzgerald
Prakhar Agrawal
Overweight
initiated
2025-08-15
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
2025-08-15
initiated
Overweight
Reason
Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Avalo Therapeutics with an Overweight rating and no price target. Avalo is a clinical-stage biotech company focused on autoimmune diseases, the analyst tells investors in a research note. The firm says the company's lead drug AVTX-009 is an IL-1N2 antibody currently in a Phase 2 trial for hidradenitis suppurativa with a readout expected in mid-2026.
H.C. Wainwright
Mitchell Kapoor
initiated
$15
2025-06-02
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$15
2025-06-02
initiated
Reason
H.C. Wainwright analyst Mitchell Kapoor assumed coverage of Avalo Therapeutics with a Buy rating and $15 price target. Avalo is a clinical-stage biotech company developing therapeutics for immunological diseases, the analyst tells investors in a research note. The firm says AVTX-009 is initially being developed to treat hidradenitis suppurativa, which is a large indication with an evolving standard-of-care regimen.
Jefferies
Kambiz Yazdi
Strong Buy
Initiates
$23
2025-03-25
Reason
Jefferies
Kambiz Yazdi
Price Target
$23
2025-03-25
Initiates
Strong Buy
Reason
Jefferies analyst Kambiz Yazdi initiated coverage of Avalo Therapeutics with a Buy rating and $23 price target. Avalo is a clinical stage biotechnology company focused on immunology and inflammation led by a veteran management team, the analyst tells investors in a research note. The firm says Avalo's lead asset AVTX-009 is an IL-1beta antibody in Phase 2 for the treatment of moderate to severe hidradenitis suppurativa with topline data expected in 2026. It thinks AVTX-009 is de-risked in part by lutikizumab data and that Avalo has an angle to show a differentiated profile.
Stifel
Alex Thompson
Strong Buy
Initiates
$36
2025-03-25
Reason
Stifel
Alex Thompson
Price Target
$36
2025-03-25
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Avalo Therapeutics Inc (AVTX.O) is -2.32, compared to its 5-year average forward P/E of -2.31. For a more detailed relative valuation and DCF analysis to assess Avalo Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.31
Current PE
-2.32
Overvalued PE
-0.31
Undervalued PE
-4.32
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
43.62
Current PS
15.05
Overvalued PS
1263.77
Undervalued PS
-1176.52
Financials
Annual
Quarterly
FY2025Q3
YoY :
-100.00%
0.00
Total Revenue
FY2025Q3
YoY :
+49.27%
-19.20M
Operating Profit
FY2025Q3
YoY :
-232.94%
-30.63M
Net Income after Tax
FY2025Q3
YoY :
-22.61%
-2.19
EPS - Diluted
FY2025Q3
YoY :
+41.97%
-16.37M
Free Cash Flow
FY2025Q3
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q3
YoY :
+506.82%
-27.22K
FCF Margin - %
FY2025Q3
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 829.12% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
7.1K
Volume
1
0-12
Months
100.0K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
647.4K
Volume
Months
0-12
1
69.7K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
AVTX News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
07:26:11
Avalo Therapeutics Announces Q3 EPS of $2.19, Exceeding Consensus Estimate of $1.64
2025-10-29 (ET)
2025-10-29
07:18:00
Avalo Therapeutics finishes participant enrollment for Phase 2 LOTUS trial
2025-10-01 (ET)
2025-10-01
07:13:28
Avalo Therapeutics names Boyd as Chief Business Officer and Ivanowicz as Senior Vice President of Human Resources.
Sign Up For More Events
Sign Up For More Events
News
9.0
10-29NewsfilterAvalo Therapeutics Completes Patient Enrollment in Phase 2 LOTUS Trial for AVTX-009 Targeting Hidradenitis Suppurativa Treatment
3.0
10-02NASDAQ.COMDFAS's Assets May Indicate a 15% Profit Opportunity
5.0
10-01NewsfilterAvalo Therapeutics Strengthens Leadership Team with Important New Hires in Business Development and HR
Sign Up For More News
People Also Watch
FAQ
What is Avalo Therapeutics Inc (AVTX) stock price today?
The current price of AVTX is 15.05 USD — it has decreased -2.4 % in the last trading day.
What is Avalo Therapeutics Inc (AVTX)'s business?
What is the price predicton of AVTX Stock?
What is Avalo Therapeutics Inc (AVTX)'s revenue for the last quarter?
What is Avalo Therapeutics Inc (AVTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Avalo Therapeutics Inc (AVTX)'s fundamentals?
How many employees does Avalo Therapeutics Inc (AVTX). have?